GHK-Cu for Hair Growth: What the Evidence Shows

The honest answer on GHK-Cu for hair growth is that the evidence is early. There's work in mice and in dishes of cells, and a few small human studies that mixed a copper peptide with other ingredients. A small vehicle-controlled trial tested GHK-Cu alone in a topical serum for eyebrow thinning in 18 adults over 12 weeks; it did not study scalp hair loss or injections. And the study quoted most often online tested a different copper peptide altogether.

That doesn't mean it does nothing. It means nobody can honestly tell you yet what it will do on your scalp.

What GHK-Cu is

GHK-Cu is a tiny peptide, three amino acids long (glycine, histidine and lysine), holding a single copper ion. Your body makes it, and blood levels fall with age. It has been sold in creams and serums for decades, and lately as an injectable. How it was discovered and what GHK-Cu is studied for beyond hair have their own pages.

GHK-Cu for hair growth: the studies, tier by tier

Evidence comes in tiers. Cell studies show what a molecule does in a dish, animal studies what it does in a body that isn't yours, and only human trials, ideally randomized (people assigned to treatment or a dummy by chance), show what it does in people. Here's the hair research, sorted:

The only row that is GHK-Cu alone is the mouse study. Shaved patches treated with the emulsion moved into the growth phase as early as day 6, against about day 9 for 5% minoxidil. That's a real finding in mice, not a result in people.

The human rows each carry a catch. In the 2016 trial, hair counts in a small measured patch of scalp rose by about 53 and 72 hairs in the two treated groups over six months, against about 10 on placebo, with no difference in length or thickness. But that molecule had no copper and was bonded to 5-ALA (a natural building block of heme, the iron-containing part of hemoglobin), so it isn't GHK-Cu. The 2025 series mixed its copper peptide with two established hair drugs, so the peptide's share can't be separated out.

The famous copper peptide hair study used a different molecule

If you've read that copper peptides lengthened human hair follicles in a lab, that's the 2007 Seoul National University study in the table's first row. It's careful work; it just didn't use GHK-Cu.

The researchers tested AHK-Cu, which swaps the first amino acid, glycine, for alanine. Tiny amounts made human follicles kept alive in a dish grow longer, and made dermal papilla cells multiply (the small cluster at the base of each follicle that signals it to grow).

One amino acid sounds trivial. In drug chemistry it often isn't: a single swap can change how a molecule binds, how long it lasts and what it does. An AHK-Cu result tells you something about copper peptides as a family and nothing certain about GHK-Cu.

The mix-up travels. The 2025 tattoo-delivery paper cites the AHK-Cu study as its reason to expect copper peptides to help hair. When a GHK-Cu hair claim traces back to "human follicles in a dish", check which molecule the paper's methods name.

On the scalp or by injection: does the route matter?

Most copper peptide hair products are serums and lotions. The catch is getting through skin: GHK-Cu dissolves easily in water and crosses the skin barrier poorly, as the mouse study's authors note, which is why they built a special emulsion to carry it.

Injection skips the barrier, which is one argument people make for it. But no published study has tested injected GHK-Cu on its own for hair, in people or animals. The closest is a 2018 study that injected a growth-factor mix, including a copper peptide listed as copper tripeptide-1, into 1,000 scalps with no comparison group (Kapoor and Shome, Journal of Cosmetic and Laser Therapy 2018).

As of September 22, 2026, the day this article was written, the injection trend had reached national news: a September 7 NPR report found dermatologists advising patients to hold off on injecting it, and noted that many people buy injectable versions from grey-market online sellers. FDA's own note on compounded injectable GHK-Cu flags a possible risk of immune reactions from clumped peptide or impurities, and says human safety data are limited (FDA, page current as of April 22, 2026).

That's the case for the prescribed route. A grey-market vial comes with no one who has read your history and no label you can trust. A prescription comes with a named provider who can decline, a licensed U.S. compounding pharmacy whose label states what's in the vial, and someone to call if something feels off.

GHK-Cu also turns up inside blends. KLOW combines it with BPC-157, TB-500 and KPV in one injectable. No study has tested the blend for hair, so the same caution applies to it as a whole.

TB-500, another ingredient in KLOW, has its own hair-growth claims; the TB-500 hair-growth evidence traces them to animal and cell studies of its larger parent protein, thymosin beta-4.

Where GHK-Cu stands with the FDA

GHK-Cu has never had a U.S.-approved product. Through Promise it is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

As of September 22, 2026, the day this article was written, FDA's advisory committee page lists GHK-Cu for discussion at a meeting "before the end of February 2027," with no date set (FDA, page current as of April 15, 2026). Committees advise; they don't decide. The timeline is in where GHK-Cu's FDA review stands.

A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies. For hair, that review should weigh the thin evidence, the route, your history (including any copper-handling or liver problems) and what you've already tried.

What a clinician may discuss for hair loss

Hair loss has several causes, and the cause shapes what's worth trying. Two medicines carry FDA labeling specifically for pattern hair loss. Finasteride 1 mg tablets are labeled for men only (Propecia label, revised August 2022). Minoxidil is sold over the counter as a foam or solution for thinning on the top of the scalp (Men's Rogaine Drug Facts).

Those are what a clinician may raise alongside any question about GHK-Cu. Whether a copper peptide belongs next to them, no trial has answered.

What would change the answer

One study would settle much of this: GHK-Cu alone, in people with a diagnosed type of hair loss, assigned by chance against a placebo, with hair counts measured for at least six months and side effects recorded.

As of September 22, 2026, the day this article was written, that trial doesn't exist. The newest systematic review of GHK-Cu in aesthetic medicine (Aesthetic Surgery Journal, published online August 20) counted 20 studies of GHK-Cu used alone: 18 in cells or animals and two randomized human trials, both measuring skin rather than hair. ClinicalTrials.gov lists registered GHK-Cu trials in wound healing, facial skin and blood levels, and none for hair. The wider gap in GHK-Cu human evidence goes beyond hair.

Until that changes, the biology is interesting, the mouse data are encouraging, and the human data on GHK-Cu itself for scalp hair are missing. Anyone promising you regrowth is ahead of the science.